Acrivon Therapeutics, Inc.
ACRV • NASDAQ
Acrivon Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Peter Blume-Jensen, with a market cap of $60.1M.
Market Cap$60.1M
Employees61.0
CEOPeter Blume-Jensen
CountryUnited States of America
Healthcare
Biotechnology
Next EarningsMay 13, 2026 · in a monthQ1 2026
Financials
ACR
Acrivon Therapeutics, Inc. FAQ
Common questions about Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. is scheduled to report earnings for Q1 2026 on May 13, 2026. Analysts estimate revenue of $788.7K.
Acrivon Therapeutics, Inc. has approximately 61 employees.